News
13 Apr 2021
Pipeline - Brivaracetam Oral Solution Product Profile
Brivaracetam 10mg/ml Oral Solution
Reference Product: Briviact® / UCB
Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.
Dossier Status: On-going (EU CTD Available: Q4 2022)
Stability Studies: Zone II / Zone IVb
Shelf life (Originator): Four (4) years
Batch Size: To be defined
Pack Sizes: To be defined / Originator pack: BT x 1 Glass Bottle.
Mentioned Companies
ANFARM HELLAS S.A.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance